Solutions available for licensing

ADMiER

ADMiER reduces the time required to diagnose dry eye disease from an estimated 18 minutes of chair-time to just three minutes. Help us enhance clinical outcomes for patients with more accurate disease characterisation through licensing. 

Bio-Dash

Accelerate the development of this practically-focused wellbeing program through licensing or direct investment. Bio-Dash is a practical and engaging wellbeing program that equips individuals to self-manage their mental health using evidence-based strategies and personal feedback. 

Broad and ultra-potent anti-HIV-1 antibodies 

Accelerate the development of broad and ultra-potent anti-HIV-1 antibodies through licensing or direct investment.

COVID-19 vaccine platform 

A COVID-19 vaccine platform that enables rapid production of second-generation vaccines against SARS-CoV-2 variants of concern has been developed by University of Melbourne researchers.

Foundations of Wellbeing

Accelerate the development of this online wellbeing program for the workplace  through licensing or direct investment. This evidence-based online wellbeing program is designed to improve employee engagement, enjoyment and productivity at work.   

Left Write Hook

Left Write Hook equips adult survivors of sexual violence to actively take back power through an evidence-based program blending creative writing and boxing.  Accelerate the development of this recovery empowerment program for sexual abuse survivors through licensing or direct investment.

Live rabies vaccine

Rabies is usually fatal in people once symptoms appear. University of Melbourne researchers have identified a strategy for a safe live rabies vaccine that is able to overcome the limitations of inactivated vaccines. Partner with us to accelerate the development of therapeutic or prophylactic rabies vaccines. 

Monoclonal antibodies against COVID-19

New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.

New targeting strategy for lupus erythematosus

Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.

Non-invasive biomarker for diabetic neuropathy 

A biomarker produced in tears could be used in early diagnosis and monitoring of neuropathy in people with diabetes, in place of current invasive or difficult-to-access diagnostic methods.

Second-generation COVID-19 vaccine  

First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.

Tissue-engineered corneal endothelium graft 

Partner with us to license graft technology that treats corneal dysfunction. 

Ultra-thin single crystal diamond membrane

Partner with us to accelerate the development and validation of the fabrication method for single crystal diamond membranes, through licensing and/or co-development. 

MedTech pipeline

STEM pipeline

Therapeutic pipeline